Peptide Therapies

This is a physician-directed, subcutaneous program used as a supportive recovery option — not a guaranteed healing treatment. BPC-157 is a peptide originally isolated from human gastric juice and is widely studied in animal models for tissue-repair signaling, inflammation modulation, and tendon, ligament, and muscle recovery. TB-500 is related to thymosin beta-4 biology and is commonly discussed for cell migration, tissue remodeling, and broader soft-tissue recovery.

The rationale is biologically plausible, but it’s important to be candid about the evidence base: a 2025 clinical review noted that the large majority of published BPC-157 research comes from animal studies produced by one research group, and that independent, controlled human trials are still scarce.  A recent peer-reviewed primer for orthopedic and sports medicine physicians similarly concluded that BPC-157’s benefits for tendon and muscle repair are “largely unvalidated in human trials,” based on a single small human case series without a control group. A 2025 pilot study did find that a short course of intravenous BPC-157 was well tolerated in two healthy adults, which is reassuring but far from proof of effectiveness. We present this program as a supportive adjunct to a broader recovery plan (rest, physical therapy, nutrition), not as a stand-alone cure.

NAD+ is involved in cellular energy metabolism, mitochondrial function, and DNA repair signaling. B12 supports normal neurologic function and red blood cell production, and can be especially helpful for patients who are deficient. Our program is positioned as a supportive wellness treatment for energy and recovery, with individualized dosing — not as a proven anti-aging or disease-modifying therapy. Persistent or worsening fatigue should always be evaluated by a physician rather than assumed to be an NAD+/B12 issue.

GHK-Cu is a copper-binding tripeptide studied for its role in collagen support, skin remodeling, and post-procedure skin recovery. We offer GHK-Cu as a topical treatment or procedure-adjunct — not as a systemic injection. The FDA has specifically identified compounded injectable GHK-Cu as a substance of concern because of limited human safety data and the potential for immune reactions, and injectable GHK-Cu remains outside the FDA’s approved compounding pathway.[9] Topical use has a more established safety track record, which is why it’s our recommended route.

Patients can choose our GHK-Cu topical cream with or without added low-dose estradiol, compounded per individual prescription. GHK-Cu is included primarily for its collagen-support and skin-remodeling properties, while the estradiol is included because topical estrogen has its own separate, more established research base in dermatology — small clinical studies and a 2025 systematic review in the Journal of the American Academy of Dermatology have evaluated topical estrogen formulations for improving skin thickness, hydration, and elasticity, particularly in postmenopausal patients, though the review’s authors noted that evidence is still limited by small sample sizes, short trial durations, and the fact many studies used compounded, non-FDA-approved formulations.  Combining the two ingredients in one cream is a compounding choice, not an FDA-approved combination product, and we’re transparent about that distinction with every patient.

Adding estradiol is not appropriate for every patient. Because even small amounts of topical estradiol are absorbed into the bloodstream, patients using the estradiol version need the same screening we’d use for any estrogen-containing product — see the estradiol-specific safety considerations later in this document. Patients who prefer to avoid systemic hormone exposure altogether can select the GHK-Cu-only formulation, which does not carry these same considerations.

Our GHK-Cu skin renewal cream is available in two formulations, compounded to your provider’s prescription:

• GHK-Cu topical cream — GHK-Cu alone, for patients focused on general skin-quality support, collagen signaling, and post-procedure recovery.
• GHK-Cu + estradiol topical cream — GHK-Cu combined with a low-dose topical estradiol, for select patients (typically peri- or post-menopausal women) seeking additional support for skin thickness, elasticity, and hydration alongside GHK-Cu’s collagen-signaling effects.

Adding estradiol changes the risk profile, so the combination formula is reserved for patients who complete additional screening. Topical estrogen can be absorbed systemically depending on the dose, application site, and skin barrier condition, and unopposed estrogen exposure carries a known risk of endometrial hyperplasia in patients who still have a uterus. For that reason, the GHK-Cu + estradiol cream is not appropriate for patients who are pregnant or breastfeeding, have a personal history of estrogen-sensitive cancer (including certain breast cancers), have an unexplained history of vaginal bleeding, or have a personal or strong family history of blood clots, stroke, or heart attack. Your provider will review your hormonal and cancer history, and may recommend periodic monitoring, before prescribing the estradiol-containing version. Patients who prefer to avoid systemic hormone exposure altogether can use the GHK-Cu-only formulation and still receive the peptide’s collagen-support benefits.

Semaglutide and tirzepatide are peptide-based metabolic medications that work through appetite and satiety signaling. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both the GIP and GLP-1 receptors. Combined with nutrition, exercise, and medical follow-up, both can reduce appetite and support meaningful weight loss. FDA-approved branded versions (Wegovy, Ozempic, Zepbound, Mounjaro) have substantial clinical-trial evidence behind them. Compounded versions are not FDA-approved and are not equivalent to the branded products — a distinction we’ll always be transparent about.